Drug Approval | September 20, 2024
Briefs: Dr. Reddy's Laboratories and Torrent Pharmaceuticals
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The acquisition is based on an enterprise value of Rs. 1,660 crore
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Subscribe To Our Newsletter & Stay Updated
